AGENT study update with regards to COVID-19
GOTHENBURG, Sweden, July 10, 2020 – Isofol Medical AB (publ) (Nasdaq First North Premier Growth Market: ISOFOL), informs that the outbreak of COVID-19 has affected the general situation of the AGENT study activities. Patient recruitment has been ongoing without interruption during the pandemic, but the effects of COVID-19 may result in a delay of the full enrolment by up to three months.As hospitals, regions and countries have updated their guidelines, Isofol has adapted accordingly to be fully compliant with the new procedures. In order to ensure continuity of the ongoing AGENT study in a